Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on June 20, 2016. The report addresses the resignation of a Board member and refutes specific allegations made in a third-party research report titled "Pershing Gold And ChromaDex Exposed" by Bleecker Street Research.
Key Financial Metrics and Operational Data
- Revenue: First quarter 2016 revenue was $7.3 million, representing a 70% increase over the fourth quarter of 2015.
- Revenue Composition: Ingredients sales accounted for 63% of total revenue in Q1 2016 ($4,600,626). In 2015, ingredients sales totaled $12,542,000, comprising 57% of total revenue.
- Related Party Transactions: HealthSpan Research, LLC (managed by Board member Rob Fried) has placed only one order for Niagen totaling less than $50,000 to date.
- Stock Promotion Payments: Payments to SmallCap Network totaled approximately $40,000, all occurring between 2011 and 2012.
- Ownership: Resigning Director William D. Smithburg owns 640,000 shares of Company common stock.
Material Changes and Corporate Events
- Board Resignation: William D. Smithburg resigned as a member of the Board of Directors effective immediately on June 20, 2016. He cited the malicious nature of the Bleecker Report as the reason for his departure, though he intends to remain an investor.
- Revenue Growth: The filing highlights a significant 70% quarter-over-quarter revenue increase driven by ingredients sales, which the Company attributes to an independent third-party customer rather than related-party transactions.
Management Commentary, Risks, and Contingencies
Management explicitly refutes several claims made in the Bleecker Report:
- Profitability Claims: The Company denies that recent profitability was engineered or the result of related-party transactions. The largest customer is an independent third party, not HealthSpan or a distributor.
- Distributor Control: The Company states that HealthSpan is a customer, not a distributor, and is not among the Company's 20 largest customers year-to-date.
- Stock Promotion: Allegations of recent stock promotion are denied; cited payments occurred five years prior to the filing.
- Shareholder Ownership: The Company states that neither David Blech nor his wife, Margie Chassman, has owned stock in the Company since 2011.
Risk Note: The filing indicates the Company is the subject of a public report alleging financial irregularities and fraud, which prompted a Board resignation.
Investor Verification Checklist
- Verify the identity of the "single largest customer" driving the 70% revenue increase in Q1 2016.
- Confirm the total value and terms of the supply agreement with HealthSpan Research, LLC.
- Review the Company's 10-Q or 10-K filings to validate the breakdown of ingredients sales versus other revenue streams.
- Check current beneficial ownership filings (Forms 3, 4, 5) to confirm the absence of David Blech or Margie Chassman as shareholders.
- Assess the potential impact of the Bleecker Report on the Company's stock price and investor sentiment.